Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 54 entries
Sorted by: Best Match Show Resources per page
[Prophylactic cranial irradiation in patients with extensive disease caused by small-cell lung cancer responsive to chemotherapy: fewer symptomatic brain metastases and improved survival].

Nederlands tijdschrift voor geneeskunde

Slotman BJ, Faivre-Finn C, Kramer GW, Rankin E, Snee M, Hatton M, Postmus PE, Collette L, Musat E, Senan S.
PMID: 18549175
Ned Tijdschr Geneeskd. 2008 Apr 26;152(17):1000-4.

OBJECTIVE: To determine the effect of prophylactic cranial irradiation (PCI) in patients with extensive-disease small-cell lung cancer (ED-SCLC) who responded to chemotherapy.DESIGN: Randomised, controlled clinical trial; phase III study (EORTC nr 08993-22993; www.clinicaltrials.gov, nr NCT00016211).METHOD: Patients aged 18-75 years...

Cite
Slotman BJ, Faivre-Finn C, Kramer GW, et al. Profylactische schedelbestraling bij patiënten met uitgebreid kleincellig longcarcinoom dat reageert op chemotherapie: minder symptomatische hersenmetastasen en betere overleving. [Prophylactic cranial irradiation in patients with extensive disease caused by small-cell lung cancer responsive to chemotherapy: fewer symptomatic brain metastases and improved survival]. Ned Tijdschr Geneeskd. 2008;152(17):1000-4
Slotman, B. J., Faivre-Finn, C., Kramer, G. W., Rankin, E., Snee, M., Hatton, M., Postmus, P. E., Collette, L., Musat, E., & Senan, S. (2008). Profylactische schedelbestraling bij patiënten met uitgebreid kleincellig longcarcinoom dat reageert op chemotherapie: minder symptomatische hersenmetastasen en betere overleving. [Prophylactic cranial irradiation in patients with extensive disease caused by small-cell lung cancer responsive to chemotherapy: fewer symptomatic brain metastases and improved survival]. Nederlands tijdschrift voor geneeskunde, 152(17), 1000-4.
Slotman, B J, et al. "Profylactische schedelbestraling bij patiënten met uitgebreid kleincellig longcarcinoom dat reageert op chemotherapie: minder symptomatische hersenmetastasen en betere overleving." [Prophylactic cranial irradiation in patients with extensive disease caused by small-cell lung cancer responsive to chemotherapy: fewer symptomatic brain metastases and improved survival]. Nederlands tijdschrift voor geneeskunde vol. 152,17 (2008): 1000-4.
Slotman BJ, Faivre-Finn C, Kramer GW, Rankin E, Snee M, Hatton M, Postmus PE, Collette L, Musat E, Senan S. Profylactische schedelbestraling bij patiënten met uitgebreid kleincellig longcarcinoom dat reageert op chemotherapie: minder symptomatische hersenmetastasen en betere overleving. [Prophylactic cranial irradiation in patients with extensive disease caused by small-cell lung cancer responsive to chemotherapy: fewer symptomatic brain metastases and improved survival]. Ned Tijdschr Geneeskd. 2008 Apr 26;152(17):1000-4. Dutch. PMID: 18549175.
Copy Download .nbib Format: NLM
The use of volunteers to implement electronic patient reported outcomes in lung cancer outpatient clinics.

Technical innovations & patient support in radiation oncology

Ala-Aldeen K, Stones N, Woolf D, Bayman N, Coote J, Harris M, Pemberton L, Sheikh H, Chan C, Hodgson C, Yorke J, Faivre-Finn C.
PMID: 32095576
Tech Innov Patient Support Radiat Oncol. 2018 Jun 05;7:11-16. doi: 10.1016/j.tipsro.2018.05.002. eCollection 2018 Sep.

BACKGROUND: Treatment related toxicity is common after chemotherapy and radiotherapy. Our group has developed and validated an electronic Patient Reported Outcome questionnaire (ePRO) to assess symptoms and toxicity in lung cancer patients receiving (chemo)radiotherapy treatment. We assessed the need...

Cite
Ala-Aldeen K, Stones N, Woolf D, et al. The use of volunteers to implement electronic patient reported outcomes in lung cancer outpatient clinics. Tech Innov Patient Support Radiat Oncol. 2018;7:11-16doi: 10.1016/j.tipsro.2018.05.002.
Ala-Aldeen, K., Stones, N., Woolf, D., Bayman, N., Coote, J., Harris, M., Pemberton, L., Sheikh, H., Chan, C., Hodgson, C., Yorke, J., & Faivre-Finn, C. (2018). The use of volunteers to implement electronic patient reported outcomes in lung cancer outpatient clinics. Technical innovations & patient support in radiation oncology, 711-16. https://doi.org/10.1016/j.tipsro.2018.05.002
Ala-Aldeen, Kardo, et al. "The use of volunteers to implement electronic patient reported outcomes in lung cancer outpatient clinics." Technical innovations & patient support in radiation oncology vol. 7 (2018): 11-16. doi: https://doi.org/10.1016/j.tipsro.2018.05.002
Ala-Aldeen K, Stones N, Woolf D, Bayman N, Coote J, Harris M, Pemberton L, Sheikh H, Chan C, Hodgson C, Yorke J, Faivre-Finn C. The use of volunteers to implement electronic patient reported outcomes in lung cancer outpatient clinics. Tech Innov Patient Support Radiat Oncol. 2018 Jun 05;7:11-16. doi: 10.1016/j.tipsro.2018.05.002. eCollection 2018 Sep. PMID: 32095576; PMCID: PMC7033755.
Copy Download .nbib Format: NLM
Changes in the Management of Patients having Radical Radiotherapy for Lung Cancer during the First Wave of the COVID-19 Pandemic in the UK.

Clinical oncology (Royal College of Radiologists (Great Britain))

Banfill K, Croxford W, Fornacon-Wood I, Wicks K, Ahmad S, Britten A, Carson C, Dorey N, Hatton M, Hiley C, Thippu Jayaprakash K, Jegannathen A, Koh P, Panakis N, Peedell C, Pope A, Powell C, Stilwell C, Thomas B, Toy E, Wood V, Yahya S, Zhou SY, Price G, Faivre-Finn C.
PMID: 34763964
Clin Oncol (R Coll Radiol). 2021 Oct 28; doi: 10.1016/j.clon.2021.10.009. Epub 2021 Oct 28.

AIMS: In response to the COVID-19 pandemic, guidelines on reduced fractionation for patients treated with curative-intent radiotherapy were published, aimed at reducing the number of hospital attendances and potential exposure of vulnerable patients to minimise the risk of COVID-19...

Cite
Banfill K, Croxford W, Fornacon-Wood I, et al. Changes in the Management of Patients having Radical Radiotherapy for Lung Cancer during the First Wave of the COVID-19 Pandemic in the UK. Clin Oncol (R Coll Radiol). 2021;doi: 10.1016/j.clon.2021.10.009.
Banfill, K., Croxford, W., Fornacon-Wood, I., Wicks, K., Ahmad, S., Britten, A., Carson, C., Dorey, N., Hatton, M., Hiley, C., Thippu Jayaprakash, K., Jegannathen, A., Koh, P., Panakis, N., Peedell, C., Pope, A., Powell, C., Stilwell, C., Thomas, B., Toy, E., Wood, V., Yahya, S., Zhou, S. Y., Price, G., & Faivre-Finn, C. (2021). Changes in the Management of Patients having Radical Radiotherapy for Lung Cancer during the First Wave of the COVID-19 Pandemic in the UK. Clinical oncology (Royal College of Radiologists (Great Britain)), . https://doi.org/10.1016/j.clon.2021.10.009
Banfill, K, et al. "Changes in the Management of Patients having Radical Radiotherapy for Lung Cancer during the First Wave of the COVID-19 Pandemic in the UK." Clinical oncology (Royal College of Radiologists (Great Britain)) vol. (2021). doi: https://doi.org/10.1016/j.clon.2021.10.009
Banfill K, Croxford W, Fornacon-Wood I, Wicks K, Ahmad S, Britten A, Carson C, Dorey N, Hatton M, Hiley C, Thippu Jayaprakash K, Jegannathen A, Koh P, Panakis N, Peedell C, Pope A, Powell C, Stilwell C, Thomas B, Toy E, Wood V, Yahya S, Zhou SY, Price G, Faivre-Finn C. Changes in the Management of Patients having Radical Radiotherapy for Lung Cancer during the First Wave of the COVID-19 Pandemic in the UK. Clin Oncol (R Coll Radiol). 2021 Oct 28; doi: 10.1016/j.clon.2021.10.009. Epub 2021 Oct 28. PMID: 34763964; PMCID: PMC8552552.
Copy Download .nbib Format: NLM
Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer.

Clinical and translational radiation oncology

Haslett K, Koh P, Hudson A, Ryder WD, Falk S, Mullan D, Taylor B, Califano R, Blackhall F, Faivre-Finn C.
PMID: 33748440
Clin Transl Radiat Oncol. 2021 Feb 25;28:24-31. doi: 10.1016/j.ctro.2021.02.008. eCollection 2021 May.

BACKGROUND: The RAS/RAF/MEK/ERK signalling pathway has a pivotal role in cancer proliferation and modulating treatment response. Selumetinib inhibits MEK and enhances effects of radiotherapy in preclinical studies.PATIENTS AND METHODS: Single-arm, single-centre, open-label phase I trial. Patients with stage III...

Cite
Haslett K, Koh P, Hudson A, et al. Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer. Clin Transl Radiat Oncol. 2021;28:24-31doi: 10.1016/j.ctro.2021.02.008.
Haslett, K., Koh, P., Hudson, A., Ryder, W. D., Falk, S., Mullan, D., Taylor, B., Califano, R., Blackhall, F., & Faivre-Finn, C. (2021). Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer. Clinical and translational radiation oncology, 2824-31. https://doi.org/10.1016/j.ctro.2021.02.008
Haslett, K, et al. "Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer." Clinical and translational radiation oncology vol. 28 (2021): 24-31. doi: https://doi.org/10.1016/j.ctro.2021.02.008
Haslett K, Koh P, Hudson A, Ryder WD, Falk S, Mullan D, Taylor B, Califano R, Blackhall F, Faivre-Finn C. Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer. Clin Transl Radiat Oncol. 2021 Feb 25;28:24-31. doi: 10.1016/j.ctro.2021.02.008. eCollection 2021 May. PMID: 33748440; PMCID: PMC7970011.
Copy Download .nbib Format: NLM
Prophylactic cranial irradiation (PCI), hippocampal avoidance (HA) whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) in small cell lung cancer (SCLC): Where do we stand?.

Lung cancer (Amsterdam, Netherlands)

Crockett C, Belderbos J, Levy A, McDonald F, Le Péchoux C, Faivre-Finn C.
PMID: 34768007
Lung Cancer. 2021 Dec;162:96-105. doi: 10.1016/j.lungcan.2021.10.016. Epub 2021 Nov 06.

Small cell lung cancer (SCLC) is an aggressive form of lung cancer associated with an increased risk of develping brain metastases (BM), which are a significant cause of morbidity and mortality. Prophylactic cranial irradiation (PCI) was first introduced in...

Cite
Crockett C, Belderbos J, Levy A, et al. Prophylactic cranial irradiation (PCI), hippocampal avoidance (HA) whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) in small cell lung cancer (SCLC): Where do we stand?. Lung Cancer. 2021;162:96-105doi: 10.1016/j.lungcan.2021.10.016.
Crockett, C., Belderbos, J., Levy, A., McDonald, F., Le Péchoux, C., & Faivre-Finn, C. (2021). Prophylactic cranial irradiation (PCI), hippocampal avoidance (HA) whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) in small cell lung cancer (SCLC): Where do we stand?. Lung cancer (Amsterdam, Netherlands), 16296-105. https://doi.org/10.1016/j.lungcan.2021.10.016
Crockett, Cathryn, et al. "Prophylactic cranial irradiation (PCI), hippocampal avoidance (HA) whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) in small cell lung cancer (SCLC): Where do we stand?." Lung cancer (Amsterdam, Netherlands) vol. 162 (2021): 96-105. doi: https://doi.org/10.1016/j.lungcan.2021.10.016
Crockett C, Belderbos J, Levy A, McDonald F, Le Péchoux C, Faivre-Finn C. Prophylactic cranial irradiation (PCI), hippocampal avoidance (HA) whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) in small cell lung cancer (SCLC): Where do we stand?. Lung Cancer. 2021 Dec;162:96-105. doi: 10.1016/j.lungcan.2021.10.016. Epub 2021 Nov 06. PMID: 34768007.
Copy Download .nbib Format: NLM
Effect of systemic inflammation biomarkers on overall survival after lung cancer radiotherapy: a single-center large-cohort study.

Acta oncologica (Stockholm, Sweden)

Abravan A, Salem A, Price G, Faivre-Finn C, van Herk M.
PMID: 34979860
Acta Oncol. 2022 Jan 03;1-9. doi: 10.1080/0284186X.2021.2022201. Epub 2022 Jan 03.

INTRODUCTION: Recent studies suggest that immune-related cells can be recruited for anti-tumor functions as well as tumor progression and the interplay between systemic inflammation and local immune response may play a major role in the development and progression of...

Cite
Abravan A, Salem A, Price G, et al. Effect of systemic inflammation biomarkers on overall survival after lung cancer radiotherapy: a single-center large-cohort study. Acta Oncol. 2022;1-9doi: 10.1080/0284186X.2021.2022201.
Abravan, A., Salem, A., Price, G., Faivre-Finn, C., & van Herk, M. (2022). Effect of systemic inflammation biomarkers on overall survival after lung cancer radiotherapy: a single-center large-cohort study. Acta oncologica (Stockholm, Sweden), 1-9. https://doi.org/10.1080/0284186X.2021.2022201
Abravan, A, et al. "Effect of systemic inflammation biomarkers on overall survival after lung cancer radiotherapy: a single-center large-cohort study." Acta oncologica (Stockholm, Sweden) vol. (2022): 1-9. doi: https://doi.org/10.1080/0284186X.2021.2022201
Abravan A, Salem A, Price G, Faivre-Finn C, van Herk M. Effect of systemic inflammation biomarkers on overall survival after lung cancer radiotherapy: a single-center large-cohort study. Acta Oncol. 2022 Jan 03;1-9. doi: 10.1080/0284186X.2021.2022201. Epub 2022 Jan 03. PMID: 34979860.
Copy Download .nbib Format: NLM
Learning healthcare systems and rapid learning in radiation oncology: Where are we and where are we going?.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Price G, Mackay R, Aznar M, McWilliam A, Johnson-Hart C, van Herk M, Faivre-Finn C.
PMID: 34619237
Radiother Oncol. 2021 Nov;164:183-195. doi: 10.1016/j.radonc.2021.09.030. Epub 2021 Oct 04.

Learning health systems and rapid-learning are well developed at the conceptual level. The promise of rapidly generating and applying evidence where conventional clinical trials would not usually be practical is attractive in principle. The connectivity of modern digital healthcare...

Cite
Price G, Mackay R, Aznar M, et al. Learning healthcare systems and rapid learning in radiation oncology: Where are we and where are we going?. Radiother Oncol. 2021;164:183-195doi: 10.1016/j.radonc.2021.09.030.
Price, G., Mackay, R., Aznar, M., McWilliam, A., Johnson-Hart, C., van Herk, M., & Faivre-Finn, C. (2021). Learning healthcare systems and rapid learning in radiation oncology: Where are we and where are we going?. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 164183-195. https://doi.org/10.1016/j.radonc.2021.09.030
Price, Gareth, et al. "Learning healthcare systems and rapid learning in radiation oncology: Where are we and where are we going?." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology vol. 164 (2021): 183-195. doi: https://doi.org/10.1016/j.radonc.2021.09.030
Price G, Mackay R, Aznar M, McWilliam A, Johnson-Hart C, van Herk M, Faivre-Finn C. Learning healthcare systems and rapid learning in radiation oncology: Where are we and where are we going?. Radiother Oncol. 2021 Nov;164:183-195. doi: 10.1016/j.radonc.2021.09.030. Epub 2021 Oct 04. PMID: 34619237.
Copy Download .nbib Format: NLM
Evaluation of Prognostic and Predictive Models in the Oncology Clinic.

Clinical oncology (Royal College of Radiologists (Great Britain))

Craddock M, Crockett C, McWilliam A, Price G, Sperrin M, van der Veer SN, Faivre-Finn C.
PMID: 34922799
Clin Oncol (R Coll Radiol). 2021 Dec 15; doi: 10.1016/j.clon.2021.11.022. Epub 2021 Dec 15.

Predictive and prognostic models hold great potential to support clinical decision making in oncology and could ultimately facilitate a paradigm shift to a more personalised form of treatment. While a large number of models relevant to the field of...

Cite
Craddock M, Crockett C, McWilliam A, et al. Evaluation of Prognostic and Predictive Models in the Oncology Clinic. Clin Oncol (R Coll Radiol). 2021;doi: 10.1016/j.clon.2021.11.022.
Craddock, M., Crockett, C., McWilliam, A., Price, G., Sperrin, M., van der Veer, S. N., & Faivre-Finn, C. (2021). Evaluation of Prognostic and Predictive Models in the Oncology Clinic. Clinical oncology (Royal College of Radiologists (Great Britain)), . https://doi.org/10.1016/j.clon.2021.11.022
Craddock, M, et al. "Evaluation of Prognostic and Predictive Models in the Oncology Clinic." Clinical oncology (Royal College of Radiologists (Great Britain)) vol. (2021). doi: https://doi.org/10.1016/j.clon.2021.11.022
Craddock M, Crockett C, McWilliam A, Price G, Sperrin M, van der Veer SN, Faivre-Finn C. Evaluation of Prognostic and Predictive Models in the Oncology Clinic. Clin Oncol (R Coll Radiol). 2021 Dec 15; doi: 10.1016/j.clon.2021.11.022. Epub 2021 Dec 15. PMID: 34922799.
Copy Download .nbib Format: NLM
The UK at the Forefront of Innovative Drug-Radiotherapy Combination Clinical Trials: Introducing the CONCORDE Platform.

Clinical oncology (Royal College of Radiologists (Great Britain))

Faivre-Finn C, Brown S, Ryan A, Greystoke A.
PMID: 32107107
Clin Oncol (R Coll Radiol). 2020 Jun;32(6):358-362. doi: 10.1016/j.clon.2020.02.003. Epub 2020 Feb 24.

No abstract available.

Cite
Faivre-Finn C, Brown S, Ryan A, et al. The UK at the Forefront of Innovative Drug-Radiotherapy Combination Clinical Trials: Introducing the CONCORDE Platform. Clin Oncol (R Coll Radiol). 2020;32(6):358-362doi: 10.1016/j.clon.2020.02.003.
Faivre-Finn, C., Brown, S., Ryan, A., Greystoke, A. (2020). The UK at the Forefront of Innovative Drug-Radiotherapy Combination Clinical Trials: Introducing the CONCORDE Platform. Clinical oncology (Royal College of Radiologists (Great Britain)), 32(6), 358-362. https://doi.org/10.1016/j.clon.2020.02.003
Faivre-Finn, C, et al. "The UK at the Forefront of Innovative Drug-Radiotherapy Combination Clinical Trials: Introducing the CONCORDE Platform." Clinical oncology (Royal College of Radiologists (Great Britain)) vol. 32,6 (2020): 358-362. doi: https://doi.org/10.1016/j.clon.2020.02.003
Faivre-Finn C, Brown S, Ryan A, Greystoke A. The UK at the Forefront of Innovative Drug-Radiotherapy Combination Clinical Trials: Introducing the CONCORDE Platform. Clin Oncol (R Coll Radiol). 2020 Jun;32(6):358-362. doi: 10.1016/j.clon.2020.02.003. Epub 2020 Feb 24. PMID: 32107107.
Copy Download .nbib Format: NLM
Breaking the Glass Ceiling for Women in Academic Clinical Oncology in the UK: A Personal View.

Clinical oncology (Royal College of Radiologists (Great Britain))

Faivre-Finn C.
PMID: 27746041
Clin Oncol (R Coll Radiol). 2017 Jan;29(1):1-2. doi: 10.1016/j.clon.2016.09.022. Epub 2016 Oct 14.

No abstract available.

Cite
Faivre-Finn C. Breaking the Glass Ceiling for Women in Academic Clinical Oncology in the UK: A Personal View. Clin Oncol (R Coll Radiol). 2016;29(1):1-2doi: 10.1016/j.clon.2016.09.022.
Faivre-Finn, C. (2017). Breaking the Glass Ceiling for Women in Academic Clinical Oncology in the UK: A Personal View. Clinical oncology (Royal College of Radiologists (Great Britain)), 29(1), 1-2. https://doi.org/10.1016/j.clon.2016.09.022
Faivre-Finn, C. "Breaking the Glass Ceiling for Women in Academic Clinical Oncology in the UK: A Personal View." Clinical oncology (Royal College of Radiologists (Great Britain)) vol. 29,1 (2017): 1-2. doi: https://doi.org/10.1016/j.clon.2016.09.022
Faivre-Finn C. Breaking the Glass Ceiling for Women in Academic Clinical Oncology in the UK: A Personal View. Clin Oncol (R Coll Radiol). 2017 Jan;29(1):1-2. doi: 10.1016/j.clon.2016.09.022. Epub 2016 Oct 14. PMID: 27746041.
Copy Download .nbib Format: NLM
CONVERTed or not: what are the barriers to implementing the evidence? - Author's reply.

The Lancet. Oncology

Faivre-Finn C.
PMID: 29208382
Lancet Oncol. 2017 Nov;18(11):e628. doi: 10.1016/S1470-2045(17)30800-8. Epub 2017 Oct 31.

No abstract available.

Cite
Faivre-Finn C. CONVERTed or not: what are the barriers to implementing the evidence? - Author's reply. Lancet Oncol. 2017;18(11):e628doi: 10.1016/S1470-2045(17)30800-8.
Faivre-Finn, C. (2017). CONVERTed or not: what are the barriers to implementing the evidence? - Author's reply. The Lancet. Oncology, 18(11), e628. https://doi.org/10.1016/S1470-2045(17)30800-8
Faivre-Finn, Corinne. "CONVERTed or not: what are the barriers to implementing the evidence? - Author's reply." The Lancet. Oncology vol. 18,11 (2017): e628. doi: https://doi.org/10.1016/S1470-2045(17)30800-8
Faivre-Finn C. CONVERTed or not: what are the barriers to implementing the evidence? - Author's reply. Lancet Oncol. 2017 Nov;18(11):e628. doi: 10.1016/S1470-2045(17)30800-8. Epub 2017 Oct 31. PMID: 29208382.
Copy Download .nbib Format: NLM
R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology.

Frontiers in oncology

Verkooijen HM, Kerkmeijer LGW, Fuller CD, Huddart R, Faivre-Finn C, Verheij M, Mook S, Sahgal A, Hall E, Schultz C.
PMID: 28421162
Front Oncol. 2017 Apr 03;7:59. doi: 10.3389/fonc.2017.00059. eCollection 2017.

The pace of innovation in radiation oncology is high and the window of opportunity for evaluation narrow. Financial incentives, industry pressure, and patients' demand for high-tech treatments have led to widespread implementation of innovations before, or even without, robust...

Cite
Verkooijen HM, Kerkmeijer LGW, Fuller CD, et al. R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology. Front Oncol. 2017;7:59doi: 10.3389/fonc.2017.00059.
Verkooijen, H. M., Kerkmeijer, L. G. W., Fuller, C. D., Huddart, R., Faivre-Finn, C., Verheij, M., Mook, S., Sahgal, A., Hall, E., & Schultz, C. (2017). R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology. Frontiers in oncology, 759. https://doi.org/10.3389/fonc.2017.00059
Verkooijen, Helena M, et al. "R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology." Frontiers in oncology vol. 7 (2017): 59. doi: https://doi.org/10.3389/fonc.2017.00059
Verkooijen HM, Kerkmeijer LGW, Fuller CD, Huddart R, Faivre-Finn C, Verheij M, Mook S, Sahgal A, Hall E, Schultz C. R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology. Front Oncol. 2017 Apr 03;7:59. doi: 10.3389/fonc.2017.00059. eCollection 2017. PMID: 28421162; PMCID: PMC5378068.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 54 entries